Cue Biopharma (CUE) Cash from Operations (2017 - 2025)

Cue Biopharma has disclosed Cash from Operations across 9 years of filings, most recently posting 1076000.0 for Q4 2025.

• Cash from Operations for Q4 2025 came in at 1076000.0, up 88.08% year-over-year; the trailing twelve-month figure through Dec 2025 was 21687000.0 (up 40.3% YoY), and the FY2025 annual result was 21687000.0, up 40.3% from the prior year.
• Cash from Operations came in at 1076000.0 for Q4 2025 at Cue Biopharma, up from 9024000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1076000.0 in Q4 2025 to a low of 12848000.0 in Q2 2022.
• The 5-year median for Cash from Operations is 9777000.0 (2021), against an average of 8931008.3.
• Across the five-year window, Cash from Operations slumped 52.09% in 2021 and jumped 88.08% in 2025, its largest moves.
• Cue Biopharma's Cash from Operations stood at 10645166.0 in 2021, then increased by 1.23% to 10514000.0 in 2022, then dropped by 4.22% to 10958000.0 in 2023, then advanced by 17.61% to 9028000.0 in 2024, then soared by 88.08% to 1076000.0 in 2025.
• The last three Cash from Operations figures came in at 1076000.0 (Q4 2025), 9024000.0 (Q3 2025), and 3415000.0 (Q2 2025), per Business Quant data.